Eric Robinson, M.D. Pain Medicine - Interventional Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 829 North Dean Rd., Suite 100, Auburn, AL 36830 Phone: 334-501-2005 |
News Archive
The American Association of Critical-Care Nurses (AACN) recognizes 98 units from 78 hospitals nationwide that earned the Beacon Award for Excellence between Jan. 1, 2012, and Dec. 31, 2012.
A study performed by researchers at the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) from the Spanish National Research Council (CSIC) in collaboration with Stony Brook University (USA) proposes a new strategy for the development of new drugs based on the inhibition of tyrosine kinase enzymes, molecules that activate and trigger many cellular processes. The results have been published in the Chemistry - A European Journal.
The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over diclofenac/hyaluronic acid gel. Such an added benefit cannot be derived from the dossier, however, as the drug manufacturer did not submit any relevant data: it did not cite any studies that directly compared ingenol mebutate with diclofenac/hyaluronic acid gel, and the method chosen by the manufacturer for an indirect comparison was unsuitable.
In the month following an older heart patient's hospital discharge, there is a one in five risk of rehospitalization or death, but little is known about how these risks change over time. A new study by Yale School of Medicine researchers found that risks remain high for up to a year, but can be addressed with targeted care.
Omeros Corporation today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7 program, which is focused on the treatment of movement disorders.
› Verified 8 days ago